Table 3. Effect of Eplerinone on SDL in Mice That Received i.c.v. STZ Following Passive Avoidancea.
| sr. no. | groups | dose (mg/kg) | SDL (sec.) on day 14th (day 1) | SDL (sec.) on day 15th (day 2) |
|---|---|---|---|---|
| 1 | normal control | CMC 1 mL/kg | 16.76 ± 0.37*** | 20.6 ± 0.4*** |
| 2 | diseased (STZ) | 3.0 | 7.8 ± 0.71 | 2.10 ± 0.36 |
| 3 | standard (piracetam) | 200 | 15.10 ± 0.33*** | 26 ± 0.54*** |
| 4 | eplerinone | 4 | 9.2 ± 2.39 | 31.2 ± 9.64*** |
| 5 | 8 | 5.8 ± 1.74 | 29.60 ± 9.57*** | |
| 6 | 16 | 5.4 ± 1.28 | 38.60 ± 10.34*** |
a
Data are represented as man ± SEM (n = 10); ***(P ≤ 0.001), **(P ≤ 0.01), and *(P ≤ 0.05) symbolize highly significant, moderately significant, and significant, respectively, as compared to the STZ-treated group.